Dorian Therapeutics
acquired by Altos LabsYC S18San Francisco, US · Founded 2018 · 8 employees · 3 known investors
Find your way into Dorian Therapeutics
Sign up to see every warm intro you have to Dorian Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Dorian Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Dorian Therapeutics develops therapeutics aimed at rejuvenating tissue and treating age-related diseases. The company operates in the biotech and anti-aging therapeutics space.
Founders & leadership· Y Combinator alumni (S18)
Dorian Therapeutics was founded in 2018 by Maddalena Adorno and Benedetta di Robilant.
MA

Maddalena AdornoCo-Founder and CEOMaddalena Adorno is a researcher with background in stem cells, oncology, and aging biology who has published in peer-reviewed journals including Nature, Science, and Cell, and holds three international patents in cancer and degenerative diseases. She founded Dorian Therapeutics, a biotechnology company developing senoblockers to target aging-related cellular mechanisms, which was later acquired by Altos Labs.
Investors · 3
Related companies · 4
SFA TherapeuticsSFA Therapeutics develops oral therapeutic candidates based on deuterated short-chain fatty acids to treat autoimmune and oncologic diseases. The company's lead program, SFA-002, is in Phase 2 development for plaque psoriasis, with additional pipeline assets targeting pancreatic cancer, liver cancer, rheumatoid arthritis, and inflammatory bowel disease.
dNovodNovo develops cellular reprogramming technology that converts patient-derived cells (blood, skin, or fat) into other cell types, with an initial focus on generating new hair to treat hair loss. The company, with research origins at Stanford and Harvard, aims to eventually produce cells, tissues, and organs on demand.
Rejuvenation Technologies Inc.Rejuvenation Technologies develops mRNA therapeutics designed to extend healthspan by lengthening short telomeres, with preclinical results in fibrotic liver and lung disease. The company is moving toward clinical trials via IND-enabling studies and builds on a Stanford-patented platform.
Eat BlueprintEat Blueprint prepares meals based on longevity-focused nutritional protocols, using organic and locally-sourced ingredients while excluding gluten and seed oils.
Companies working in the same space as Dorian Therapeutics.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $452.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $335.6K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Legal entities · 1
corporate structureDorian Therapeutics, Inc.
In the news
Frequently asked questions
- What does Dorian Therapeutics do?
- Dorian Therapeutics develops therapeutics aimed at rejuvenating tissue and treating age-related diseases. The company operates in the biotech and anti-aging therapeutics space.
- Who founded Dorian Therapeutics?
- Dorian Therapeutics was founded by Maddalena Adorno, Benedetta di Robilant in 2018.
- Who are Dorian Therapeutics's investors?
- Dorian Therapeutics's investors include Blumberg Capital, StartX, Y Combinator.
- Who acquired Dorian Therapeutics?
- Dorian Therapeutics was acquired by Altos Labs.
- Where is Dorian Therapeutics headquartered?
- Dorian Therapeutics is headquartered in San Francisco, US.








